Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy

Frontiers in Immunology

Immunology

Andrew DeMaio¹  Daniel Sterman¹  Antonio Velez¹ 

[1] Pulmonary Oncology Research Team (New York University (NYU) PORT), Section of Interventional Pulmonology, Division of Pulmonary, Critical Care and Sleep Medicine, NYU Grossman School of Medicine, NYU Langone Health, New York, NY, United States;

关键词: cryoablation;    cryotherapy;    lung cancer;    immune response;    bronchoscopy;   

DOI  :  10.3389/fimmu.2023.1203539

 received in 2023-04-10, accepted in 2023-07-31,  发布年份 2023

来源: Frontiers

【 摘 要 】

Despite remarkable advances in tumor response and patient survival in the past decade, systemic immunotherapies for lung cancer result in an objective response in only around half of patients treated. On the basis of this limitation, combination strategies are being investigated to improve response rates. Cryoablation has been proposed as one such technique to induce immunogenic cell death and synergize with systemic immunotherapies, including immune checkpoint inhibitors. Cryoablation has been traditionally delivered percutaneously with imaging guidance although recent technological advances allow for bronchoscopic delivery. Herein, we review the pre-clinical and clinical evidence for the use of cryoablation in non-small cell lung cancer and potential induction of anti-tumor immunity. We highlight ongoing studies involving this approach and propose areas of future investigation.

【 授权许可】

Unknown   
Copyright © 2023 Velez, DeMaio and Sterman